Clare McGrane

M3 Biotechnology Secures $1.4M from Alzheimer’s Drug Discovery Foundation to Launch Clinical Trials for Innovative Alzheimer's Therapy

Seattle-based M3 Biotechnology secured an additional $1.4 million from the Alzheimer’s Drug Discovery Foundation to prepare clinical trials for its novel Alzheimer’s therapy aimed at stopping neuron deterioration. This funding follows a previous $14 million raised, supporting the company’s advancement toward potentially halting disease progression rather than just treating symptoms.

UW Spinout Bellwether Bio Raises $2.7M Seed to Commercialize Non‑Invasive Liquid Biopsy Founded by Jay Shendure and Matthew Snyder

Bellwether Bio, a University of Washington spinout founded by genomics researcher Jay Shendure and technologist Matthew Snyder, is commercializing a non-invasive liquid biopsy that analyzes tumor DNA in blood and raised an oversubscribed seed round totaling $2.7 million per an SEC filing. Investors include the UW’s W Fund, WRF Capital and Bioeconomy Capital, and the company says it is collaborating with cancer diagnostics firms to validate and commercialize the technology.

UW Tacoma Spinout KenSci Raises $8.5M Series A to Scale ML Platform Predicting Patient Clinical, Financial, and Operational Risks

KenSci, a University of Washington Tacoma spinout founded by Ankur Teredesai and Samir Manjure, raised $8.5 million in Series A funding to scale its machine-learning risk prediction platform that forecasts clinical, financial, and operational patient risks. The startup aggregates data from devices and electronic medical records to help health systems move from reactive disease management to proactive care.

ChoiceMap founder Jonathan Jackson raises $100,000 from angel Tom Callaghan to advance patient-centered treatment decision app

ChoiceMap, founded by cognitive-science researcher Jonathan Jackson, turned a personal decision-making algorithm into an app that helps patients and physicians choose treatment options aligned with patient preferences. The startup raised about $100,000 from angel investor Tom Callaghan to support growth and clinical trials at the University of Pittsburgh Medical Center.

Former Expedia VP Jeff Warren’s Stealth Startup Closer Mobile Raises $325,106 Including Funding from Idealab

Former Expedia executive Jeff Warren has launched a stealth startup called Closer Mobile, building an app described as a “Kayak for ride-hailing” to compare and book multiple transportation services. An SEC filing shows Closer Mobile raised $325,106, including investment from Bill Gross’ incubator Idealab, and the company plans to reveal more details later this year or early next while actively hiring.

Sound Pharmaceuticals raises $30M to advance SPI-1005 (Ebselen) into mid/late trials for noise-induced hearing loss

Sound Pharmaceuticals is raising $30 million (with just over $4 million committed so far) to fund mid- and late-stage trials of SPI-1005, an Ebselen-containing drug aimed at preventing or reversing noise-induced hearing loss. Ebselen can enter the cochlea and cross the blood-brain barrier, so SPI-1005 is being advanced for hearing loss while the compound is also studied for other ear disorders and bipolar disorder.

BrightVolt opens Series B with $5M lead from New Science Ventures, total funding tops $20M

BrightVolt, a Redmond startup making ultra-thin, solid-state Flexion batteries used in over 10,000 products, has opened a Series B round with a $5 million lead investment from New Science Ventures, bringing total funding to over $20 million. The company will use the funds to scale manufacturing and prepare for increased demand across IoT, medical devices, wearables, sensors and labels.

Seattle Serial Entrepreneur Ron Berenson’s New UW Spin‑Off DMD Therapeutics Files to Raise $600,000

Ron Berenson has launched a new Seattle biotech startup, DMD Therapeutics, which filed to raise $600,000 with Berenson listed as president; the company is a University of Washington spin-off currently operating in stealth mode. Berenson is a serial entrepreneur who leads several other biotech and medical companies and has a long history in Seattle’s biotech scene.

University of Washington Spinout C-SATS Raises $3.2M to Expand Video-Based Surgical Performance Review Platform

C-SATS, a University of Washington spinout that uses operating-room video and paid expert reviewers to assess surgeons’ technical and communication skills, raised $3.2 million to expand staff and technology after a prior $2.5 million round. The Seattle startup’s platform is now used at about 100 hospitals and was recently adopted by UW Medicine departments for broader clinical applications.

Joylux raises $2 million, hires marketing VP and advisor ahead of U.S. launch of vSculpt pelvic‑floor device

Joylux raised $2 million to prepare a U.S. launch of vSculpt, a sonic-vibration device that treats pelvic floor weakening and has already launched successfully in Canada. The company hired Heather Dazell as VP of marketing, added Deborah Reisenthel to its advisory board, and is seeking FDA clearance while having offered vSculpt for U.S. pre-sale at $345.

Online